SWI as an Alternative to Contrast-Enhanced Imaging to Detect Acute MS Lesions

Detection of multiple sclerosis lesions by susceptibility-weighted imaging-A systematic review and meta-analyses

RATIONALE AND OBJECTIVES

Susceptibility-weighted imaging (SWI) is a valuable method in the diagnosis of multiple sclerosis (MS). SWI can show diagnostic biomarkers and also distinguish MS lesions from similar diseases. This study is a systematic review and meta-analysis of the available literature to investigate the diagnostic accuracy of SWI for the detection of MS lesions in the brain, while, specific aspects of its performance were examined.

MATERIAL AND METHODS

Using specified keywords, a search of the electronic databases MEDLINE/PubMed, Scopus, Embase/Elsevier-Ovid, and Scholar databases was conducted. The search time filter ranged from the year 2010 to 2023 . Sensitivity and specificity were used as effect sizes, and SE as a precision metric (with 95% confidence interval). The study was performed according to PRISMA 2020 guidelines and the prospective register of systematic reviews (PROSPERO) registration.

RESULTS

The number of 19 studies with a total of 2026 patients to examine both automated and nonautomated assessments. The pooled sensitivities for MS lesion (MSL), paramagnetic rim lesions (PRLs), central vein sign (CVS), and PRL with CVS were 62% (53-72), 37% (17-57), and 60% (31-89). Moreover, the pooled specificities were 93% (90-97), 88% (82-94), 100% (100-100), and 78% (50-100), respectively.

CONCLUSION

Adding the SWI method to routine sequences for MS investigation can provide useful diagnostic information.

Prognostic significance of paramagnetic rim lesions in multiple sclerosis: A systematic review

The diagnostic potential of paramagnetic rim lesions (PRLs) has been previously established; however, the prognostic significance of these lesions has not previously been consistently described. This study aimed to establish the prognostic role of PRLs in MS with respect to the Expanded Disability Status Scale (EDSS) and rates of disability progression. Databases of PubMed, EMBASE, Scopus and reference lists of selected articles were searched up to 29/04/2023. The review was conducted in accordance with PRISMA guidelines and was registered prospectively on PROSPERO (CRD42023422052). 7 studies were included in the final review. All of the eligible studies found that patients with PRLs tend to have higher baseline EDSS scores. Longitudinal assessments revealed greater EDSS progression in patients with PRLs over time in most studies. However, the effect of location of PRLs within the central nervous system were not assessed across the studies. Only one study investigated progression independent of relapse activity (PIRA) and showed that this clinical entity occurred in a greater proportion in patients with PRLs. This review supports PRLs as a predictor of EDSS progression. This measure has widespread applicability, however further multicentre studies are needed. Future research should explore the impact of PRLs on silent disability, PIRA, take into account different MS phenotypes and the topography of PRLs in prognosis.

Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group

Magnetic resonance imaging (MRI) is the most sensitive technique for detecting inflammatory demyelinating lesions in multiple sclerosis (MS) and plays a crucial role in diagnosis and monitoring treatment effectiveness, and for predicting the disease course. In clinical practice, detection of MS lesions is mainly based on T2-weighted and contrast-enhanced T1-weighted sequences. Contrast-enhancing lesions (CEL) on T1-weighted sequences are related to (sub)acute inflammation, while new or enlarging T2 lesions reflect the permanent footprint from a previous acute inflammatory demyelinating event. These two types of MRI features provide redundant information, at least in regular monitoring of the disease. Due to the concern of gadolinium deposition after repetitive injections of gadolinium-based contrast agents (GBCAs), scientific organizations and regulatory agencies in Europe and North America have proposed that these contrast agents should be administered only if clinically necessary. In this article, we provide data on the mode of action of GBCAs in MS, the indications of the use of these agents in clinical practice, their value in MS for diagnostic, prognostic, and monitoring purposes, and their use in specific populations (children, pregnant women, and breast-feeders). We discuss imaging strategies that achieve the highest sensitivity for detecting CELs in compliance with the safety regulations established by different regulatory agencies. Finally, we will briefly discuss some alternatives to the use of GBCA for detecting blood-brain barrier disruption in MS lesions. CLINICAL RELEVANCE STATEMENT: Although use of GBCA at diagnostic workup of suspected MS is highly valuable for diagnostic and prognostic purposes, their use in routine monitoring is not mandatory and must be reduced, as detection of disease activity can be based on the identification of new or enlarging lesions on T2-weighted images. KEY POINTS: • Both the EMA and the FDA state that the use of GBCA in medicine should be restricted to clinical scenarios in which the additional information offered by the contrast agent is required. • The use of GBCA is generally recommended in the diagnostic workup in subjects with suspected MS and is generally not necessary for routine monitoring in clinical practice. • Alternative MRI-based approaches for detecting acute focal inflammatory MS lesions are not yet ready to be used in clinical practice.